Blueprint Medicines — ASCO 2020 Virtual Meeting
21 slides from Blueprint Medicines's conference presentation, May 29, 2020
Slide 1: Pralsetinib data review and registration program update
Pralsetinib data review and registration program update MAY 29, 2020 ASCO 2020 VIRTUAL MEETING Linnea, living with lung cancer
Slide 2: Blueprint Medicines call participants
Blueprint Medicines call participants Introduction Jeff Albers, Chief Executive Officer Pralsetinib clinical data review Andy Boral, MD, PhD, Chief Medical Officer Pralsetinib commercial strategy Christy Rossi, Chief Commercial Officer Q&A All 2 PREPARED REMARKS
Slide 3: Forward-looking statements
Forward-looking statements 3 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "
Slide 4: Pralsetinib clinical data have strengthened over time
Pralsetinib clinical data have strengthened over time 1. Presented at AACR 2018 Annual Meeting. Data cut off: April 6, 2018. 2. Presented at ASCO 2019 Annual Meeting. Data cut off: April 28, 2019. 3. Presented at ASCO 2020 Virtual Annual Meeting. Data cut off: November 18, 2019. 4. FDA has granted b
Slide 5: Broad pralsetinib registration program continues to rapidly advance
Broad pralsetinib registration program continues to rapidly advance FDA PROGRAMS DESIGNED TO EXPEDITE AND PROMOTE EFFICIENT REVIEW PROCESS Indication Breakthrough Therapy1 Real-Time Oncology Review Project Orbis Priority Review Regulatory status RET+ NSCLC ✓ ✓ ✓ • NDA accepted by FDA with November 2
Slide 6: Broad pralsetinib clinical development program in RET+ cancers
Broad pralsetinib clinical development program in RET+ cancers CBR, clinical benefit rate; DCR, disease control rate; DOR, duration of response; ORR, overall response rate; OS, overall survival; PFS, progression free survival; QD, once daily; R, randomized; TTF, time-to-treatment failure; 1º, primar
Slide 7: Pralsetinib clinical data review
Pralsetinib clinical data review Andy Boral, MD, PhD, Chief Medical Officer
Slide 8: ARROW trial baseline characteristics: RET fusion+ NSCLC
ARROW trial baseline characteristics: RET fusion+ NSCLC 8 Prior platinum (n=92) Treatment naïve (n=29) Median age (range), years 60 (28–85) 65 (30–87) ECOG PS, % 0 37 38 1 58 59 2† 5 3 Brain metastases‡, % 41 41 RET fusion partner, % KIF5B 74 69 CCDC6 17 10 Other§ 2 0 Unknown* 7 21 Prior therapy typ
Slide 9: Robust clinical activity in NSCLC patients regardless of prior therapy
Robust clinical activity in NSCLC patients regardless of prior therapy Data presented at ASCO 2020 virtual annual meeting. Data cut off: November 18, 2019. 1. Two responses pending confirmation at the time of data cut off were subsequently confirmed. CI, confidence interval. 9 61% (95% CI: 50-72%) P
Slide 10: Prolonged duration of response in NSCLC patients regardless of prior therapy
DURATION OF RESPONSE PER CENTRAL RADIOLOGY Prolonged duration of response in NSCLC patients regardless of prior therapy Data presented at ASCO 2020 virtual annual meeting. Data cut off: November 18, 2019. CR, complete response; PR, partial response. NR, not reached. 10 Not for promotional use. NR (9
Slide 11: Pralsetinib is well-tolerated in patients with advanced cancer
Pralsetinib is well-tolerated in patients with advanced cancer Data presented at ASCO 2020 virtual annual meeting. Data cut off: November 18, 2019. 1. Kocher, et al. Clinical Lung Cancer, 2014. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CV, cardiovascular; QT,
Slide 12: Complete responses lead to highly durable benefit in NSCLC patients
Complete responses lead to highly durable benefit in NSCLC patients Data cut off: November 18, 2019. 12 COMPLETE RESPONSE RATE 5% Prior platinum chemo (n=80) 12% No prior systemic therapy (n=26) DURATION OF RESPONSE PER CENTRAL RADIOLOGY All complete responses ongoing with treatment durations up to
Slide 13: High response rates in treatment-naïve NSCLC populations
High responses rates in treatment-naïve NSCLC populations consistent with real-world patients 88% Eligible for standard therapy (n=32) OVERALL RESPONSE RATE TUMOR SHRINKAGE PER INVESTIGATOR ASSESSMENTS Target population for actively enrolling AcceleRET Lung Phase 3 trial in treatment-naïve NSCLC TRE
Slide 14: High CNS CR rate and prolonged CNS duration of response in NSCLC patients
High CNS CR rate and prolonged CNS duration of response in NSCLC patients 14 • 33% intracranial CR rate • 100% with shrinkage of CNS metastases • Median CNS DOR not reached • No CNS progressive events among CNS responders Maximum percent reduction from baseline in CNS target lesion diameter 20 0 –20
Slide 15: Patient case: durable complete CNS response
Baseline After 16 months • 56 year-old female never smoker with RET-KIF5B fusion-positive NSCLC • Previously received adjuvant therapy with carboplatin/paclitaxel • Metastatic disease in brain, pleura, lymph nodes at study entry • 20 mm brain target lesion with rapid shrinkage and complete resolutio
Slide 16: Deep and durable responses in patients with RET fusion+ thyroid cancer
Deep and durable responses in patients with RET fusion+ thyroid cancer Data presented at ASCO 2020 virtual annual meeting. Data cut off: February 13, 2020. 16 TUMOR SHRINKAGE PER CENTRAL RADIOLOGY Not for promotional use. Additional pralsetinib data in patients with other RET fusion+ solid tumors to
Slide 17: Pralsetinib commercial strategy
Pralsetinib commercial strategy Christy Rossi, Chief Commercial Officer
Slide 18: Our plan to deliver a best-in-class selective RET inhibitor to patients
Our plan to deliver a best-in-class selective RET inhibitor to patients DIFFERENTIATED CLINICAL PROFILE PATIENT- AND HEALTHCARE PROVIDER-CENTERED APPROACH HIGHLY EXPERIENCED, NIMBLE TEAM Data showing deep responses, long-lasting benefit, tolerability and convenience Tailored support enabling patient
Slide 19: Questions & answers
(Sbwuepriat. Questions & answers
Slide 20: Key anticipated corporate milestones through 2H 2020
Key anticipated corporate milestones through 2H 2020 CHMP; EMA Committee for Medicinal Products for Human Use; EAACI, European Academy of Allergy and Clinical Immunology; GIST, gastrointestinal stromal tumor; ISM, indolent systemic mastocytosis; SM, systemic mastocytosis. 20 JUNE 2020 Q3 2020 Q4 202
Slide 21: Thank you
(Sbwuepriat. Thank you